Company Team Projects Media Contact


Lascco Announces a Licensing Agreement with Abbott for Development and Commercialization of Pancreatic Stone Protein Biomarker

Monday, November 26, 2012

GENEVA, SWITZERLAND -- Lascco SA announced today that its wholly-owned subsidiary Sepstone Diagnostics Sàrl has signed a licensing agreement with global healthcare company Abbott (NYSE: ABT) for the commercialization of Pancreatic Stone Protein (PSP), Sepstone’s biomarker for sepsis. Under the terms of this agreement, Abbott will have the right to develop the PSP biomarker for use on its immunochemistry analyzers globally.

About sepsis

Sepsis, a syndrome characterized by an overwhelming systemic response to infection, is among the leading causes of death in intensive care units and accounts for 40% of their total expenditure. Every year, 18 million individuals die from sepsis. In the United States alone, the estimate of cases exceeds 750’000 per year. Despite tremendous research and increasing therapeutic efforts, mortality rates from sepsis remain disappointingly high, ranging between 30% and 50%, mostly attributed to misdiagnosis or delayed diagnosis.

About Lascco SA

LASCCO SA is a Swiss-based biotechnology company dedicated to the maturation of early-stage biomedical technologies. For more information, visit


Lascco S.A.

Rue de la Rôtisserie 8 - 1211 Geneva 3 – Switzerland

Phone: +41 (0)22 317 8881